** Shares of U.S. drugmaker Eli Lilly LLY.N rise 2% to $859.99 premarket
** Co forecasts 2025 EPS between $22.50 and $24.00, above Street estimates of $22.86 at midpoint, according to data compiled by LSEG
** Co posts Q4 adj EPS of $5.32 vs estimates of $4.95, according to data compiled by LSEG
** Q4 sales of weight-loss drug Zepbound came in at $1.91 billion vs estimates of $2.03 billion -LLY
** Up to last close, stock gained 19.5% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.